Ketamine infusion therapy in treatment-resistant depression
Τheodosios Ε Christodoulakis
Psychiatriki December 20, 2021 DOI: 10.22365/jpsych.2021.051 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Intervention | Intravenous ketamine infusion |
| Topics | Depression Ketamine Esketamine |
| Keywords | Depression economics Electroconvulsive therapy Anesthesia Pharmacology Cognition |
| Citations | 1 |
| Key findings | The FDA approval of S-ketamine nasal spray represents a new category of therapeutic agents in psychiatry, and intravenous ketamine infusion has been studied for depression since the 1990s. |
Abstract
Τhe Food and Drug Administration (FDA) approval of the use of S-ketamine in the form of nasal spray for the treatment of treatment-resistant depression, launched a new category of therapeutic agents in psychiatry. A well-known class of substances, psychedelics, are introduced with a 30-year delay in the treatment of mental disorders. Intravenous ketamine infusion has been studied in the treatment of depression since the 1990s. Here we present the current protocol for the treatment of ketamine infusion in patients with treatment-resistant depression and related clinical information.
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |